Summit Therapeutics Plunges After FDA Rejects Ivonescimab Lung Cancer Application
Summit Therapeutics shares fell 19% to 20% in premarket trading after the FDA rejected ivonescimab over insufficient overall survival benefit.
Novo Nordisk’s Wegovy Pediatric Trial Points to Potential New Obesity Market
Novo Nordisk’s pediatric Wegovy trial could broaden its obesity franchise, while raising the stakes in competition with Eli Lilly.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Diamondback’s $5 Billion Permian Deal Puts US Shale Consolidation Back in the Spotlight
Diamondback Energy’s $5 billion Permian acquisition from Double Eagle highlights consolidation, acreage valuations and c…
CG Oncology Stock Rises on Positive Phase 3 Bladder Cancer Results
CG Oncology shares moved higher after positive topline Phase 3 data for cretostimogene, with full PIVOT-006 results due …
Summit Therapeutics Stock Plunges After FDA Rejects Lung Cancer Drug Application
Summit Therapeutics shares fell more than 19% in premarket trading after the FDA issued a Complete Response Letter for i…
MiNK Therapeutics’ Phase 2 Lung-Injury Trial Sets Up FDA Design Catalyst
MiNK Therapeutics’ randomized Phase 2 trial of agenT-797 could gain strategic clarity through a planned FDA discussion b…
Stoke Therapeutics Builds Commercial Infrastructure as Clinical Catalysts Approach
Stoke Therapeutics is expanding market-access teams while two data readouts approach, but preparation is not proof of ap…
Cocrystal Pharma’s Widening Loss Meets Fresh OPKO Backing and Norovirus Trial Progress
Nasdaq-listed COCP reported a wider $3.44 million quarterly loss alongside Phase 1b progress and a $5 million OPKO inves…
Norfolk Southern–Union Pacific Deal Spread Widens as CEO Remarks Stir Uncertainty
The widening spread between Norfolk Southern and Union Pacific puts deal timing and regulatory approval risk back in foc…
FTC Threat to Block $3.5 Billion Covetrus-MWI Deal Raises Stakes for M&A Traders
A reported FTC lawsuit over the $3.5 billion Covetrus-MWI deal highlights regulatory risk for merger arbitrage and healt…
Viking Therapeutics Takeover Chatter Puts VKTX Back in the M&A Spotlight
Renewed takeover interest lifted VKTX shares, sharpening the debate over obesity-drug consolidation and the risks of M&A…